English

Avidity Biosciences, Inc.

EDGAR

RNA Current report (8-K) · filed 2026-02-27

Annual consolidated revenue for 2025: about USD 18.76M, using the latest reported figures. The previous period, 2024, was about USD 10.9M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

860 thousand USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 18755000 USD Source
Revenue: 17895000 USD Source

Operating margin

-29,590.47%

2025 Q4 · %

Exact inputs and evidence

Operating Income: -745943000 USD Source
Operating Income: -491465000 USD Source
Revenue: 18755000 USD Source
Revenue: 17895000 USD Source

Operating cash flow

-170 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -650441000 USD Source
Operating Cash Flow: -480668000 USD Source

Free cash flow

-175 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -650441000 USD Source
Operating Cash Flow: -480668000 USD Source
Capital Expenditure: 13319000 USD Source
Capital Expenditure: 7808000 USD Source

Cash and cash equivalents: 383 million USD 2025-12-31 Source
Exact value

382500000 USD
Long-term debt including current maturities: 0 USD 2020-09-30 Source
Exact value

0 USD
Shares outstanding: 151 million shares 2025-12-31 Source
Exact value

151205000 shares

Reported share-count change

26.12% · 31.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

119893000 shares · 2024-12-31· Source
151205000 shares · 2025-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

18.8 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 1573000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 3847000 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 12475000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 18755000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 17895000 USD · 2025-01-01 – 2025-09-30 Source

Net income

-685 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Net income: -115773000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -157315000 USD · 2025-04-01 – 2025-06-30 Source
Net income: -174442000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -684631000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -447530000 USD · 2025-01-01 – 2025-09-30 Source

Operating cash flow

-650 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Operating cash flow: -124829000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -324495000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -124829000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -480668000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -324495000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -650441000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -480668000 USD · 2025-01-01 – 2025-09-30 Source

Capital expenditure

13.3 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Capital expenditure: 3753000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 7096000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 3753000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 7808000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 7096000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 13319000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 7808000 USD · 2025-01-01 – 2025-09-30 Source

Free cash flow

-664 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Operating cash flow: -124829000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -324495000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -124829000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -480668000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -324495000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -650441000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -480668000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3753000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 7096000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 3753000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 7808000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 7096000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 13319000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 7808000 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-02-27.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2019-12-31
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+72.1%

Prior period

USD 10.9 million

2024-01-01 – 2024-12-31
Current period

USD 18.76 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

18755000 − 10897000 = 7858000 USD

10897000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
18755000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Year-over-year change in Revenue: 7858000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 18755000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1820954 Filing: 000159990126000031 Input fundies:Revenue: 10897000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1821826 Filing: 000159990126000031
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 362.33 million

Prior period

−USD 322.3 million

2024-01-01 – 2024-12-31
Current period

−USD 684.63 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-684631000 − -322302000 = -362329000 USD

-322302000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-684631000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Year-over-year change in Net income: -362329000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -684631000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1943884 Filing: 000159990126000031 Input fundies:NetIncome: -322302000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1917130 Filing: 000159990126000031
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 349.57 million

Prior period

−USD 300.87 million

2024-01-01 – 2024-12-31
Current period

−USD 650.44 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-650441000 − -300870000 = -349571000 USD

-300870000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-650441000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Year-over-year change in Operating cash flow: -349571000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -650441000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1979904 Filing: 000159990126000031 Input fundies:OperatingCashFlow: -300870000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1980551 Filing: 000159990126000031
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+88.5%

Prior period

USD 7.07 million

2024-01-01 – 2024-12-31
Current period

USD 13.32 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

13319000 − 7066000 = 6253000 USD

7066000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
13319000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Year-over-year change in Capital expenditure: 6253000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 13319000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1986693 Filing: 000159990126000031 Input fundies:CapitalExpenditure: 7066000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1987278 Filing: 000159990126000031
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 18.76 million 100% of revenue
Operating costs Derived USD 764.7 million 4,077% of revenue
Operating income −USD 745.94 million −3,977% of revenue
Tax, interest and other Derived −USD 61.31 million −327% of revenue
Net income −USD 684.63 million −3,650% of revenue

Cash

Operating cash flow −USD 650.44 million −3,468% of revenue
Capital expenditure USD 13.32 million 71% of revenue
Free cash flow Derived −USD 663.76 million −3,539% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 2,870% of revenue.
2019 Operating loss: operating costs were 847% of revenue.
2020 Operating loss: operating costs were 752% of revenue.
2021 Operating loss: operating costs were 1,366% of revenue.
2022 Operating loss: operating costs were 2,040% of revenue.
2023 Operating loss: operating costs were 2,564% of revenue.
2024 Operating loss: operating costs were 3,577% of revenue.
2025 Operating loss: operating costs were 4,077% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	379000	10877000 Derived	-10498000	718000 Derived	-11216000	-9704000 Derived	Source 2018-01-01 – 2018-12-31: 379000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -10498000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -11216000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -9655000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 49000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	2319000	19651000 Derived	-17332000	7402000 Derived	-24734000	2255000 Derived	Source 2019-01-01 – 2019-12-31: 2319000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -17332000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -24734000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 2490000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 235000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	6787000	51064000 Derived	-44277000	78000 Derived	-44355000	-38209000 Derived	Source 2020-01-01 – 2020-12-31: 6787000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -44277000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -44355000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -37117000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1092000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	9326000	127377000 Derived	-118051000	-42000 Derived	-118009000	-98553000 Derived	Source 2021-01-01 – 2021-12-31: 9326000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -118051000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -118009000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -94813000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3740000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	9224000	188137000 Derived	-178913000	-4918000 Derived	-173995000	-139091000 Derived	Source 2022-01-01 – 2022-12-31: 9224000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -178913000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -173995000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -136268000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 2823000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	9560000	245158000 Derived	-235598000	-23378000 Derived	-212220000	-123292000 Derived	Source 2023-01-01 – 2023-12-31: 9560000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -235598000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -212220000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -119064000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 4228000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	10897000	389833000 Derived	-378936000	-56634000 Derived	-322302000	-307936000 Derived	Source 2024-01-01 – 2024-12-31: 10897000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -378936000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -322302000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -300870000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 7066000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	18755000	764698000 Derived	-745943000	-61312000 Derived	-684631000	-663760000 Derived	Source 2025-01-01 – 2025-12-31: 18755000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -745943000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -684631000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -650441000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 13319000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 18.8M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	379000	Revenue: 379000 Open source
20192019-12-31	Revenue	2319000	Revenue: 2319000 Open source
20202020-12-31	Revenue	6787000	Revenue: 6787000 Open source
20212021-12-31	Revenue	9326000	Revenue: 9326000 Open source
20222022-12-31	Revenue	9224000	Revenue: 9224000 Open source
20232023-12-31	Revenue	9560000	Revenue: 9560000 Open source
20242024-12-31	Revenue	10897000	Revenue: 10897000 Open source
20252025-12-31	Revenue	18755000	Revenue: 18755000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

72.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 379000 Open source
20192019-12-31	Year over year	511.9%	Revenue: 2319000 Open source Revenue: 379000 Open source
20202020-12-31	Year over year	192.7%	Revenue: 6787000 Open source Revenue: 2319000 Open source
20212021-12-31	Year over year	37.4%	Revenue: 9326000 Open source Revenue: 6787000 Open source
20222022-12-31	Year over year	-1.1%	Revenue: 9224000 Open source Revenue: 9326000 Open source
20232023-12-31	Year over year	3.6%	Revenue: 9560000 Open source Revenue: 9224000 Open source
20242024-12-31	Year over year	14%	Revenue: 10897000 Open source Revenue: 9560000 Open source
20252025-12-31	Year over year	72.1%	Revenue: 18755000 Open source Revenue: 10897000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3,977.3% 2025

Net margin -3,650.4% 2025

Free cash flow margin -3,539.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-2,769.9%	Operating Income: -10498000 Open source Revenue: 379000 Open source
20192019-12-31	Operating margin	-747.4%	Operating Income: -17332000 Open source Revenue: 2319000 Open source
20202020-12-31	Operating margin	-652.4%	Operating Income: -44277000 Open source Revenue: 6787000 Open source
20212021-12-31	Operating margin	-1,265.8%	Operating Income: -118051000 Open source Revenue: 9326000 Open source
20222022-12-31	Operating margin	-1,939.6%	Operating Income: -178913000 Open source Revenue: 9224000 Open source
20232023-12-31	Operating margin	-2,464.4%	Operating Income: -235598000 Open source Revenue: 9560000 Open source
20242024-12-31	Operating margin	-3,477.4%	Operating Income: -378936000 Open source Revenue: 10897000 Open source
20252025-12-31	Operating margin	-3,977.3%	Operating Income: -745943000 Open source Revenue: 18755000 Open source
20182018-12-31	Net margin	-2,959.4%	Net Income: -11216000 Open source Revenue: 379000 Open source
20192019-12-31	Net margin	-1,066.6%	Net Income: -24734000 Open source Revenue: 2319000 Open source
20202020-12-31	Net margin	-653.5%	Net Income: -44355000 Open source Revenue: 6787000 Open source
20212021-12-31	Net margin	-1,265.4%	Net Income: -118009000 Open source Revenue: 9326000 Open source
20222022-12-31	Net margin	-1,886.3%	Net Income: -173995000 Open source Revenue: 9224000 Open source
20232023-12-31	Net margin	-2,219.9%	Net Income: -212220000 Open source Revenue: 9560000 Open source
20242024-12-31	Net margin	-2,957.7%	Net Income: -322302000 Open source Revenue: 10897000 Open source
20252025-12-31	Net margin	-3,650.4%	Net Income: -684631000 Open source Revenue: 18755000 Open source
20182018-12-31	Free cash flow margin	-2,560.4%	Revenue: 379000 Open source Operating Cash Flow: -9655000 Open source Capital Expenditure: 49000 Open source
20192019-12-31	Free cash flow margin	97.2%	Revenue: 2319000 Open source Operating Cash Flow: 2490000 Open source Capital Expenditure: 235000 Open source
20202020-12-31	Free cash flow margin	-563%	Revenue: 6787000 Open source Operating Cash Flow: -37117000 Open source Capital Expenditure: 1092000 Open source
20212021-12-31	Free cash flow margin	-1,056.8%	Revenue: 9326000 Open source Operating Cash Flow: -94813000 Open source Capital Expenditure: 3740000 Open source
20222022-12-31	Free cash flow margin	-1,507.9%	Revenue: 9224000 Open source Operating Cash Flow: -136268000 Open source Capital Expenditure: 2823000 Open source
20232023-12-31	Free cash flow margin	-1,289.7%	Revenue: 9560000 Open source Operating Cash Flow: -119064000 Open source Capital Expenditure: 4228000 Open source
20242024-12-31	Free cash flow margin	-2,825.9%	Revenue: 10897000 Open source Operating Cash Flow: -300870000 Open source Capital Expenditure: 7066000 Open source
20252025-12-31	Free cash flow margin	-3,539.1%	Revenue: 18755000 Open source Operating Cash Flow: -650441000 Open source Capital Expenditure: 13319000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -650.4M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-9655000	Operating Cash Flow: -9655000 Open source
20192019-12-31	Operating cash flow	2490000	Operating Cash Flow: 2490000 Open source
20202020-12-31	Operating cash flow	-37117000	Operating Cash Flow: -37117000 Open source
20212021-12-31	Operating cash flow	-94813000	Operating Cash Flow: -94813000 Open source
20222022-12-31	Operating cash flow	-136268000	Operating Cash Flow: -136268000 Open source
20232023-12-31	Operating cash flow	-119064000	Operating Cash Flow: -119064000 Open source
20242024-12-31	Operating cash flow	-300870000	Operating Cash Flow: -300870000 Open source
20252025-12-31	Operating cash flow	-650441000	Operating Cash Flow: -650441000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -663.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-9704000	Operating Cash Flow: -9655000 Open source Capital Expenditure: 49000 Open source
20192019-12-31	Free cash flow	2255000	Operating Cash Flow: 2490000 Open source Capital Expenditure: 235000 Open source
20202020-12-31	Free cash flow	-38209000	Operating Cash Flow: -37117000 Open source Capital Expenditure: 1092000 Open source
20212021-12-31	Free cash flow	-98553000	Operating Cash Flow: -94813000 Open source Capital Expenditure: 3740000 Open source
20222022-12-31	Free cash flow	-139091000	Operating Cash Flow: -136268000 Open source Capital Expenditure: 2823000 Open source
20232023-12-31	Free cash flow	-123292000	Operating Cash Flow: -119064000 Open source Capital Expenditure: 4228000 Open source
20242024-12-31	Free cash flow	-307936000	Operating Cash Flow: -300870000 Open source Capital Expenditure: 7066000 Open source
20252025-12-31	Free cash flow	-663760000	Operating Cash Flow: -650441000 Open source Capital Expenditure: 13319000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

13.8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Liabilities / assets	Not reported	No source recorded
20192019-12-31	Liabilities / assets	28.4%	Total Liabilities: 27544000 Open source Total Assets: 96907000 Open source
20202020-12-31	Liabilities / assets	8.3%	Total Liabilities: 27675000 Open source Total Assets: 333898000 Open source
20212021-12-31	Liabilities / assets	10.8%	Total Liabilities: 46150000 Open source Total Assets: 427580000 Open source
20222022-12-31	Liabilities / assets	9.5%	Total Liabilities: 60725000 Open source Total Assets: 638800000 Open source
20232023-12-31	Liabilities / assets	20.3%	Total Liabilities: 127791000 Open source Total Assets: 628555000 Open source
20242024-12-31	Liabilities / assets	8.9%	Total Liabilities: 138936000 Open source Total Assets: 1563895000 Open source
20252025-12-31	Liabilities / assets	13.8%	Total Liabilities: 269450000 Open source Total Assets: 1958050000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.2× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
20192019-12-31	Current assets / current liabilities	9.35×	Current Assets: 95676000 Open source Current Liabilities: 10236000 Open source
20202020-12-31	Current assets / current liabilities	22.74×	Current Assets: 331678000 Open source Current Liabilities: 14587000 Open source
20212021-12-31	Current assets / current liabilities	13.86×	Current Assets: 411141000 Open source Current Liabilities: 29658000 Open source
20222022-12-31	Current assets / current liabilities	12×	Current Assets: 622942000 Open source Current Liabilities: 51908000 Open source
20232023-12-31	Current assets / current liabilities	7.58×	Current Assets: 611307000 Open source Current Liabilities: 80680000 Open source
20242024-12-31	Current assets / current liabilities	15.73×	Current Assets: 1542290000 Open source Current Liabilities: 98018000 Open source
20252025-12-31	Current assets / current liabilities	9.2×	Current Assets: 1798467000 Open source Current Liabilities: 195446000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 11.22 million Exact value Exact value: -11216000 USD 2018-01-01 – 2018-12-31: -11216000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2018-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -11216000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11216000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459021013157/rna-20201231.xml#135763 Filing: 000156459021013157 The citation records this snapshot. The page link may show a newer release later.	−USD 9.66 million Exact value Exact value: -9655000 USD 2018-01-01 – 2018-12-31: -9655000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2018-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -9655000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9655000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459021013157/rna-20201231.xml#170596 Filing: 000156459021013157 The citation records this snapshot. The page link may show a newer release later.	USD 49,000 Exact value Exact value: 49000 USD 2018-01-01 – 2018-12-31: 49000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2018-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 49000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 49000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459021013157/rna-20201231.xml#171814 Filing: 000156459021013157 The citation records this snapshot. The page link may show a newer release later.	−USD 9.7 million Calculation and evidence -9655000 − 49000 USD Exact free cash flow: -9704000 USD 2018-01-01 – 2018-12-31: -9655000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 49000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2018-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -9704000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9655000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459021013157/rna-20201231.xml#170596 Filing: 000156459021013157 Input fundies:CapitalExpenditure: 49000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459021013157/rna-20201231.xml#171814 Filing: 000156459021013157 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 24.73 million Exact value Exact value: -24734000 USD 2019-01-01 – 2019-12-31: -24734000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2019-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -24734000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24734000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459022008049/rna-10k_20211231.htm#1697590 Filing: 000156459022008049 The citation records this snapshot. The page link may show a newer release later.	USD 2.49 million Exact value Exact value: 2490000 USD 2019-01-01 – 2019-12-31: 2490000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2019-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: 2490000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2490000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459022008049/rna-10k_20211231.htm#2595411 Filing: 000156459022008049 The citation records this snapshot. The page link may show a newer release later.	USD 235,000 Exact value Exact value: 235000 USD 2019-01-01 – 2019-12-31: 235000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2019-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 235000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 235000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459022008049/rna-10k_20211231.htm#2617437 Filing: 000156459022008049 The citation records this snapshot. The page link may show a newer release later.	USD 2.26 million Calculation and evidence 2490000 − 235000 USD Exact free cash flow: 2255000 USD 2019-01-01 – 2019-12-31: 2490000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 235000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2019-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: 2255000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 2490000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459022008049/rna-10k_20211231.htm#2595411 Filing: 000156459022008049 Input fundies:CapitalExpenditure: 235000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000156459022008049/rna-10k_20211231.htm#2617437 Filing: 000156459022008049 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 44.36 million Exact value Exact value: -44355000 USD 2020-01-01 – 2020-12-31: -44355000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2020-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -44355000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44355000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990123000009/rna-20221231.htm#1149765 Filing: 000159990123000009 The citation records this snapshot. The page link may show a newer release later.	−USD 37.12 million Exact value Exact value: -37117000 USD 2020-01-01 – 2020-12-31: -37117000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2020-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -37117000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37117000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990123000009/rna-20221231.htm#1293553 Filing: 000159990123000009 The citation records this snapshot. The page link may show a newer release later.	USD 1.09 million Exact value Exact value: 1092000 USD 2020-01-01 – 2020-12-31: 1092000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2020-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 1092000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1092000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990123000009/rna-20221231.htm#1303598 Filing: 000159990123000009 The citation records this snapshot. The page link may show a newer release later.	−USD 38.21 million Calculation and evidence -37117000 − 1092000 USD Exact free cash flow: -38209000 USD 2020-01-01 – 2020-12-31: -37117000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1092000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2020-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -38209000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37117000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990123000009/rna-20221231.htm#1293553 Filing: 000159990123000009 Input fundies:CapitalExpenditure: 1092000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990123000009/rna-20221231.htm#1303598 Filing: 000159990123000009 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 118.01 million Exact value Exact value: -118009000 USD 2021-01-01 – 2021-12-31: -118009000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2021-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -118009000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -118009000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000025/rna-20231231.htm#1099578 Filing: 000159990124000025 The citation records this snapshot. The page link may show a newer release later.	−USD 94.81 million Exact value Exact value: -94813000 USD 2021-01-01 – 2021-12-31: -94813000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2021-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -94813000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -94813000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000025/rna-20231231.htm#1190971 Filing: 000159990124000025 The citation records this snapshot. The page link may show a newer release later.	USD 3.74 million Exact value Exact value: 3740000 USD 2021-01-01 – 2021-12-31: 3740000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2021-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 3740000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3740000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000025/rna-20231231.htm#1197604 Filing: 000159990124000025 The citation records this snapshot. The page link may show a newer release later.	−USD 98.55 million Calculation and evidence -94813000 − 3740000 USD Exact free cash flow: -98553000 USD 2021-01-01 – 2021-12-31: -94813000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3740000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2021-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -98553000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -94813000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000025/rna-20231231.htm#1190971 Filing: 000159990124000025 Input fundies:CapitalExpenditure: 3740000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000025/rna-20231231.htm#1197604 Filing: 000159990124000025 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 174 million Exact value Exact value: -173995000 USD 2022-01-01 – 2022-12-31: -173995000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2022-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -173995000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -173995000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990125000059/rna-20241231.htm#1162215 Filing: 000159990125000059 The citation records this snapshot. The page link may show a newer release later.	−USD 136.27 million Exact value Exact value: -136268000 USD 2022-01-01 – 2022-12-31: -136268000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2022-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -136268000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -136268000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990125000059/rna-20241231.htm#1254239 Filing: 000159990125000059 The citation records this snapshot. The page link may show a newer release later.	USD 2.82 million Exact value Exact value: 2823000 USD 2022-01-01 – 2022-12-31: 2823000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2022-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 2823000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2823000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990125000059/rna-20241231.htm#1260884 Filing: 000159990125000059 The citation records this snapshot. The page link may show a newer release later.	−USD 139.09 million Calculation and evidence -136268000 − 2823000 USD Exact free cash flow: -139091000 USD 2022-01-01 – 2022-12-31: -136268000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2823000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2022-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -139091000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -136268000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990125000059/rna-20241231.htm#1254239 Filing: 000159990125000059 Input fundies:CapitalExpenditure: 2823000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990125000059/rna-20241231.htm#1260884 Filing: 000159990125000059 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 212.22 million Exact value Exact value: -212220000 USD 2023-01-01 – 2023-12-31: -212220000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2023-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -212220000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -212220000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1883381 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	−USD 119.06 million Exact value Exact value: -119064000 USD 2023-01-01 – 2023-12-31: -119064000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2023-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -119064000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -119064000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1981199 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	USD 4.23 million Exact value Exact value: 4228000 USD 2023-01-01 – 2023-12-31: 4228000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2023-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 4228000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4228000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1987863 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	−USD 123.29 million Calculation and evidence -119064000 − 4228000 USD Exact free cash flow: -123292000 USD 2023-01-01 – 2023-12-31: -119064000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 4228000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2023-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -123292000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -119064000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1981199 Filing: 000159990126000031 Input fundies:CapitalExpenditure: 4228000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1987863 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 322.3 million Exact value Exact value: -322302000 USD 2024-01-01 – 2024-12-31: -322302000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2024-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -322302000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -322302000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1917130 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	−USD 300.87 million Exact value Exact value: -300870000 USD 2024-01-01 – 2024-12-31: -300870000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2024-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -300870000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -300870000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1980551 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	USD 7.07 million Exact value Exact value: 7066000 USD 2024-01-01 – 2024-12-31: 7066000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2024-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 7066000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7066000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1987278 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	−USD 307.94 million Calculation and evidence -300870000 − 7066000 USD Exact free cash flow: -307936000 USD 2024-01-01 – 2024-12-31: -300870000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 7066000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2024-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -307936000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -300870000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1980551 Filing: 000159990126000031 Input fundies:CapitalExpenditure: 7066000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1987278 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 684.63 million Exact value Exact value: -684631000 USD 2025-01-01 – 2025-12-31: -684631000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Net Income: -684631000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -684631000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1943884 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	−USD 650.44 million Exact value Exact value: -650441000 USD 2025-01-01 – 2025-12-31: -650441000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Operating Cash Flow: -650441000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -650441000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1979904 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	USD 13.32 million Exact value Exact value: 13319000 USD 2025-01-01 – 2025-12-31: 13319000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Capital Expenditure: 13319000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13319000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1986693 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.	−USD 663.76 million Calculation and evidence -650441000 − 13319000 USD Exact free cash flow: -663760000 USD 2025-01-01 – 2025-12-31: -650441000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 13319000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Avidity Biosciences, Inc. · 2025-12-31 Avidity Biosciences, Inc. (edgar:1599901) Free cash flow: -663760000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:32:29Z Snapshot: 89736badd71c11713f2500210d03ee6320f629c587b58fbc9d7b446903e0a8ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -650441000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1979904 Filing: 000159990126000031 Input fundies:CapitalExpenditure: 13319000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599901/000159990126000031/rna-20251231.htm#1986693 Filing: 000159990126000031 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 1,778 latest values · 1,778 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001599901, 1599901, RNA, RNAM, edgar:1599901

Also known as AVIDITY BIOSCIENCES, INC., Avidity Biosciences LLC, Avidity Biosciences, Inc., Avidity NanoMedicines LLC

Avidity Biosciences, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation